Why the EU should support the standardization of health outcomes measurements

18 October 2018

When the European Commission published its report on the State of Health in the European Union last year, it recognized five ongoing trends in health system reform: shifting to prevention, stronger primary care, integration of care, supporting a resilient health workforce and developing better patient-centered data.

All these developments are important to make European healthcare systems more sustainable despite mounting pressure from an ageing population and multi-morbidities. The fifth trend however, which is also the most aspirational one, is the key to making European healthcare systems truly patient-centered and outcomes-based, comments Thomas Allvin, executive director, strategy and healthcare systems at trade group the European Federation of Pharmaceutical Industries and Associations (EFPIA) in a blog posting.

What do we mean by outcomes-based?

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK